Repositioning Candidate Details
| Candidate ID: | R0804 |
| Source ID: | DB05451 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | P54 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | P54 reduces the inflammation associated with cancer/tumors, Crohn's disease, inflammatory bowel disease, osteoarthritis, and ulcerative colitis. It inhibits the induction of the enzyme NFkB, thereby inhibiting downstream inflammatory genes such as COX II and iNOS. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in cancer/tumors (unspecified), crohn's disease, inflammatory bowel disease, osteoarthritis, and ulcerative colitis. |
| DrugBank Pharmacology: | P54 inhibits the induction of the enzyme NFkB, thereby inhibiting downstream inflammatory genes such as COX II and iNOS. |
| DrugBank MoA: | P54 inhibits the induction of the enzyme NFkB, thereby inhibiting downstream inflammatory genes such as COX II and iNOS. |
| Targets: | Nuclear factor NF-kappa-B p100 subunit; Nuclear factor NF-kappa-B p105 subunit |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |